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Summary A study has been carried out to investigate the cellular distribution and levels of glutathione-S-
transferase isoenzymes (GST), acidic (7t), basic (x) and neutral (p), in ovarian tumour biopsies, and to measure
GST activity in the same tumour specimens. Two methods of assessing isoenzyme levels (immunohistochem-
istry and Western blot) were compared. Well-known important clinicopathological features were correlated
with response to treatment, overall survival and progression-free survival for each of 97 patients from whom
biopsies had been obtained. The glutathione-S-transferase isoenzyme levels were also correlated with overall
and progression-free survival, and with the important clinicopathological features. As expected, there was a
significant correlation between FIGO stage, histological grade of tumour, amount of residual disease after
staging laparotomy, response to chemotherapy, and both overall and progression-free survival. Glutathione-S-
transferase isoenzyme levels (acidic, basic and neutral) measured by Western blot were not found to be
significantly correlated with any of the clinicopathalogical parameters tested. Using the immunohistochemistry
method of detection there was a correlation between the GST acidic isoenzyme level and the amount of
residual disease remaining after initial debulking surgery (higher levels were detected in the group with no
residual disease, P=0.034), and also between the GST acidic isoenzyme level and the type of chemotherapy
regimen used. Higher levels of the acidic isoenzyme were present in tumour biopsies taken from the patient
group who had received a combination regimen (cyclophosphamide, carboplatin, ifosfamide and doxorubicin).
The neutral and basic GST isoenzyme levels were not significantly correlated with any of the
clinicopathalogical parameters. None of the GST isoenzyme levels were significantly correlated with response
to treatment, overall survival or progression-free survival (using either method of detection). Similarly,
glutathione transferase activity showed no significant correlation with prognosis or survival.
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There are a number of well-known important prognostic
clinicopathological features in ovarian cancer, including
tumour stage, grade and volume of residual disease
remaining after primary surgery. However, it often remains
difficult to predict which patients will respond well to
chemotherapy treatment and have a prolonged interval free
of progressive disease. The glutathione transferase enzymes
are a group of cytosolic proteins capable of catalysing
detoxification pathways involved in the breakdown of a
number of chemotherapeutic agents (Mannervik and
Danielson, 1988). Certain of the isoenzymes have been
implicated as markers of early disease recurrence in node-
negative breast cancer (i isoenzyme) (Gilbert et al., 1993),
squamous cell oral cancer (x isoenzyme) (Hirata et al., 1992),
childhood acute lymphoblastic leukaemia (y isoenzyme) (Hall
et al., 1994) and acute non-lymphoblastic leukaemia (7x
isoenzyme) (Tidefelt et al., 1992).
The levels and activity of the GST isoenzymes were,
therefore, measured in ovarian tumour samples obtained
from patients undergoing primary surgical treatment for their
disease (n =66). The results were correlated with a number of
important prognostic features, including the patient's age,
tumour stage, grade and histology and also with response to
subsequent chemotherapy, progression-free survival and
overall survival. Measurements were also carried out on
specimens obtained from patients after chemotherapy
(n = 31), and an attempt was made to relate any changes to
the type of chemotherapy the patient had received.
Materials and methods
Patients and biopsy specimens
Fresh ovarian tumour specimens were collected from patients
undergoing laparotomy for suspected ovarian cancer (n =66)
and from patients having second-look procedures (n=31) at
hospitals throughout the north-west region. The selection of
patients was entirely random and depended upon gynaecol-
ogy surgeons contacting the author (EW) who then attended
the laparotomy to obtain fresh biopsies. Tumour samples
were immediately frozen in liquid nitrogen and stored at
-80'C until required. Tumour grade and histological type
were confirmed by central pathology review in 82 cases and
by the referring hospital in 15 cases. The presence of
malignant tissue in biopsy specimens was confirmed by
routine histological staining at the time of processing.
Clinicopathological characteristics
Of the 97 patients, 82 were referred to the Christie Hospital
for chemotherapy and 15 continued to be managed at the
hospital where surgery was undertaken. The pathological
features of each tumour specimen were documented together
with details of chemotherapy and response to treatment. The
details of the tumour pathology and the mode of patient
management of the 15 patients not treated with adjuvant
therapy at the Christie Hospital were obtained by review of
case notes at the referring hospital by the author. The
availability of follow-up data restricted the sample size to just
less than 100 patients. All patients were followed up until the
time of death or until February 1995. All surviving patients
were followed for at least 6 months after completing
chemotherapy treatment.
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Chemotherapy regimens
Fifteen patients received no chemotherapy either because they
had stage IA disease (n= 10) or because they were considered
too unfit for chemotherapy (n= 5).
Fifty-seven patients received a combination regimen
(carboplatin 300 mg m-2 and cyclophosphamide 600 mg
m-2, alternating with doxorubicin 50 mg m-2 and ifosfa-
mide 5 g m-2) in either 3 or 4 weekly cycles.
Twenty-four patients received single agent therapy. Of
these, 19 received melphalan (10 mg p.o. daily for 5 days,
every 6 weeks), three received carboplatin (300 mg m-2 and
i.v. every 3 weeks) and two received cyclophosphamide
(1 g m-2 i.v. every 3 weeks).
Classification of response to treatment
Patients were described as having a complete response to
treatment if a CAT scan performed after chemotherapy
showed no residual disease (complete clinical response), or if
at second-look laparotomy there was no pathological
evidence of disease (complete pathological response). A
partial response was defined as a greater than 50% reduction
in the product of two perpendicular measurements of tumour
size on CAT scan post-treatment. Static disease was defined
when there was a less than 50% regression and less than 25%
increase in size of a similar tumour load before and after
chemotherapy, and progressive disease when tumour size was
seen to increase by more than 25%, or when any new lesions
were seen on the post-treatment CAT scan.
The survival time was calculated from the date of initial
laparotomy to the date of death, or date the patient was last
seen for follow-up. The progression-free survival was
calculated from the date of documented disease progression.
The median follow-up time of the group as a whole was 22.7
months, 19.3 months for the first-look group and 26.2
months for the second-look group.
Patients with no apparent residual disease on CAT scan
after primary radical surgery were not assessable for response
to treatment unless the patient had microscopic or
macroscopic residual disease which was found to have
disappeared at the time of second-look laparotomy.
Immunohistochemistry
All chemicals were supplied by Sigma unless otherwise stated.
Three rabbit polyclonal antibodies raised against glutathione-
S-transferase acidic (X), basic (a) and neutral (j) isoenzymes
(a gift from A Hall, Newcastle) (Murphy et al., 1992) were
used to determine the distribution of the isoenzymes in 97
human ovarian carcinoma specimens. Four micron-embedded
sections were fixed in 4% formalin, dewaxed, alcohol fixed,
air dried and rehydrated in phosphate-buffered saline (PBS).
Endogenous peroxidase was blocked using 30% hydrogen
peroxide and 0.3 g of sodium azide in 3.3 ml of PBS for
10 min. Following incubation in swine serum the primary
antibodies were added (1:400 dilution for 30 min at 25°C).
Slides were washed twice in PBS and incubated with the
secondary antibody (swine anti-rabbit peroxidase, Dako
1:100, 30 min). The peroxidase reaction was developed using
diaminobenzidine (0.5 mg ml-') and hydrogen peroxide
(0.03%).
Slides were counterstained in Mayer's haematoxylin. For
the negative control the primary antibody was substituted by
control rabbit IgG. At each staining session a sample of
tissue (liver) known to express the relevant enzyme was
processed as a positive control.
Scoring Each stained tumour section was examined and
scored by two independent workers. Scoring was graded
either negative (1), few scattered cells (2), <20% cells
positive (3), 20% or more positive (4).
Preparation of tissue homogenates
Tissue was thawed and homogenised in buffer (0.1 M
potassium phospate, pH 6.8, at 4°C) using a Polytron 3000
mechanical blender. Homogenates were then centrifuged
(MSE microfuge, 2 min, max speed 12 000 g) and the clear
supernatant extracted. The protein concentration of the
supernatants was determined using the Bio-Rad protein
assay system according to the manufacturer's instructions.
Measurement ofglutathione-S-transferase activity
Enzyme activity in the ovarian tumour specimens was
measured spectrophotometrically using 1-chloro-2, 4-dinitro-
benzene (CDNB) and glutathione as co-substrates (Habig et
al., 1974). Enzyme activities were standardised for protein
content. Cell homogenates were incubated with CDNB
(1 mM) in potassium phosphate buffer (0.1 M, pH 6.5 at
37°C) and the increase in absorbance measured at 350 nm on
a Cary 1 spectrophotometer.
Western blot assays
Extracts of 86 tumour proteins (25 Mg) were combined with
buffer (Laemmli, 1970) and electrophoresed using a Bio-Rad
Mini-Protean II cell system. Resolved proteins were
electroblotted onto nitrocellulose membranes. After blocking
with 5% Marvel in Tris-buffered saline (TBS), membranes
were incubated with GST acidic, basic and neutral antibodies
and subsequently with peroxidase-conjugated swine anti-
rabbit and streptavidin. Immunodetection was carried out
using an ECL Western blot detection kit (Amersham)
according to the manufacturer's instructions.
A 5 ug sample of purified GST (Sigma) was electrophor-
esed on each gel and used as an internal reference against
which ovarian biopsy samples could be compared in order to
quantify the relative amounts of GST acidic, basic and
neutral isoenzymes. Each of the GST isoenzymes demon-
strated a single band at approximately 23 000 Da.
The amount of each isoenzyme in each 25 jg sample of
ovarian tumour protein was quantified using a Logitech
scanner by comparing the area under the curve with the area
under the curve for purified GST (5 jig) after incubation with
the same isoenzyme.
Statistical analysis
Survival curves were calculated by the method of Kaplan and
Meier (1958). The Kruksal-Wallis test was used to compare
each of the clinicopathological variables with the Western
blot GST isoenzyme values (jig per jg protein sample). Chi-
square tests were used to compare the GST immunohisto-
chemistry results with clinicopathological variables. Each of
the clinicopathological variables was correlated with survival
and progression-free survival using the chi-square test.
Results
The distribution of the clinicopathological parameters in the
97 ovarian tumours (66 prechemotherapy and 31 post-
chemotherapy) is illustrated in Table I. In a univariate
analysis well-known clinicopathological prognostic features
of ovarian cancer (including tumour differentiation, FIGO
stage, post-operative residual disease status) were found to be
significantly correlated with both overall survival and disease-
free survival (Table I). Where such parameters were found to
be significant, this applied to the group as a whole (n=97)
and to the prechemotherapy (n =66) and post-chemotherapy
groups (n = 31) independently.
Immunohistochemistry
Table II shows the GST isoenzyme levels and the
demographic data for all the patients from whom biopsieswere obtained. Positive GST isoenzyme staining was seen in
the cytoplasm of malignant cells of the ovarian tumour
sections. Only a few tumours demonstrated nuclear staining-
all of these were in the acidic isoenzyme class where the
staining was very intense and therefore most probably a
result of diffusion into the nuclei. For the purposes of the
analysis tumour sections were scored as negative, <20%
positive cells stained, >20% positive cells stained, as in
previous studies carried out in the laboratory (Murphy et al.,
1992). The distribution of the GST isoenzymes in histologi-
cally confirmed tumour cells was acidic (i): 15 negative, 82
positive; basic (a): 31 negative, 66 positive; and neutral (M): 47
negative, 50 positive. GST acidic isoenzymes demonstrated
the most intense staining in this group. No significant
correlation was found between any of the three GST
isoenzyme levels detected immunohistochemically and re-
sponse to treatment, progression-free or overall survival,
either in the group as a whole (n=97) or when subdivided
into prechemotherapy and post-chemotherapy specimens. A
significant correlation was found between tumour levels of
GST acidic isoenzyme and the treatment group comprising
combination chemotherapy (P=0.025). Within this group
approximately equal numbers of specimens were obtained
before chemotherapy at initial surgery (n=31) and after
chemotherapy at second-look laparotomy (n=26). The GST
acidic isoenzyme levels in biopsies taken before chemotherapy
would not be expected to influence the type of chemotherapy
selected for the patient. However, post-chemotherapy GST
acidic isoenzyme levels may be relevant with regard to the
type of treatment which had been received. When considering
the post-treatment group alone the correlation between GST
acidic isoenzyme level and type of treatment received by the
patient was no longer significant, however, this was only a
small group (n=26). In addition, there was no correlation
between the group of patients receiving the combination
treatment and overall survival or progression-free survival.
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The basic and neutral GST isoenzyme levels were not
correlated significantly with any of the clinicopathological
parameters tested.
Western blot assays
Western blot detection of GST isoenzyme levels was carried
out on 86 ovarian biopsy samples. The results are shown in
detail in Table II. Figure 1 shows an example of a Western
blot of seven tumour proteins and purified GST (5 Mg) in lane
1, stained for the acidic isoenzyme. The amount ofisoenzyme
in a given sample of tumour protein was calculated and the
result expressed as ,ug of GST isoenzyme per 5 ug of tumour
protein. Whereas, using the immunohistochemistry method of
detection some of the tumour biopsies were scored negative
for each isoenzyme (acidic 15.5%, basic 32%, neutral 48%),
a value for each GST isoenzyme measured using the Western
blot technique was obtained in all 86 tumour samples
electrophoresed. There was a positive correlation between
the isoenzyme levels detected by immunohistochemistry and
those detected by Western blot analysis: acidic (P=0.008),
basic (P=0.027) and neutral (P=0.006), indicating some
consistency between the two methods. The Western blot
technique, however, was found to be more sensitive, detecting
isoenzyme levels which had been missed by observer
examination of the stained ovarian tumour sections.
No significant correlation was found between GST
isoenzyme levels detected by Western blot and response to
treatment, progression-free or overall survival. In addition,
the Kruskal-Wallis test failed to reveal any significant
correlations between the GST isoenzyme levels in tumour
biopsies and any of the important clinicopathological
parameters. These results applied to analysis of the whole
series (86 tumours) and when the group was subdivided into
pre and post-chemotherapy specimens.
There was no significant difference in GST isoenzyme
Table I Distribution of clinicopathological parameters in 97 ovarian tumours, and relationship to overall
survival
survival and progression-free
No. ofpatients
Clinicopathological Overall Progression-
parameter First look" Second lookc survival' free survival
Age
<50 13 10
<60 16 6 P-0.271 P=0.652
< 70 24 11 NS NS
>70 13 4
Tumour grade/differentiation
Well 14 8 P=0.019 P=0.015
Moderately 24 8 Sig Sig
Poor 27 16
FIGO stage
I 8 2
II 3 3 P=0.004 P=0.004
III 29 14 Sig Sig
IV 26 12
Histological
Mucinous 9 2
Serous 25 9 P=0.629 P=0.592
Endometrioid 17 14 NS NS
Unclassified 15 6
Post-operative status
No residual 13 5 P<0.0001 P=0.0001
<2 cm 18 12 Sig Sig
>2 cm 35 14
Response to treatment
Complete response 14 9
Partial response 17 11 P<0.0001 P<0.0001
Static disease 3 3 Sig Sig
Progressive disease 23 7
Not assessible 8 2
aOverall survival andprogression-free survival: P<0.005 issignificant. Theresultsshown areforthegroup as awhole(n =97). b1stlook,biopsies
taken from patients at initial staging laparotomy. c2nd look, biopsies taken from patients who had undergone adjuvant chemotherapy.GST activity and isoenzyme levels in ovarian cancer
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Figure 1 Western blot of protein extracts (25,g) of seven
tumour proteins (lanes 2-8) and purified GST (5 g) in lane 1,
stained for the acidic isoenzyme.
levels in ovarian biopsy samples taken prechemotherapy (first
look) and those taken after chemotherapy treatment (second
look), using either method of detection. This applied also to
three patients for whom sequential samples were obtained.
Unfortunately, because second-look procedures were not
routine at this hospital only a limited number of sequential
(pre- and post-chemotherapy) samples were available for
analysis.
Glutathione transferase activity
This was measured in all 97 ovarian tumours and the results
expressed as mol`0 conjugate min- mg-' protein. Measure-
ments on each sample were made in triplicate and in Table II
the results are detailed as the mean of the three readings.
There was a wide range of values from <10 x I00-mol
conjugate minm mg-' protein to >90 x 10'-l mol conjugate
min-' mg-' protein. There was no significant difference in
GST activity in tumour samples taken prechemotherapy or
post-chemotherapy, and no correlation was found between
GST activity in the pre- or post-treatment tumour samples
and response to treatment, progression-free or overall
survival.
Discussion
In this study two methods of detecting GST isoenzyme levels
in ovarian tumour biopsies have been compared. The results
obtained using immunohistochemistry and Western blot
techniques were found to correlate for each of the acidic,
basic and netural GST isoenzyme levels. Other methods of
detecting isoenzymes have been described, including high
performance liquid chromatography (HPLC) in ovarian
tumours (Van Der Zee et al., 1992), Western blot in breast
tumours (Peters et al., 1993), Western blot and Northern
hybridisation in breast (Melina et al., 1993). All methods of
GST isoenzyme detection are subject to a degree of
experimental error. In immunohistochemistry, observer
variation in identifying positively stained cells may occur.
In addition, infiltrating cells such as lymphocytes may also
stain positively in some cases making it difficult to distinguish
them from tumour cells in a stained tissue section.
Semiquantitative methods (such as Western blot) involve
the use of homogenised tumour tissue. This inevitably results
in a degree of dilution of actual tumour protein by
surrounding fatty and fibrous tissue, vascular elements and
infiltrating inflammatory cells. Effort was made in this study
to homogenise a piece of solid tumour by dissecting away
surrounding unwanted tissue. Allowing for such experimental
errors, we found that the Western blot method was more
sensitive than immunohistochemistry for detecting GST
isoenzyme levels in ovarian tumour biopsies. In particular,
47% of the ovarian biopsies were negative for netural GST
isoenzymes and 31% were negative for basic GST isoenzymes
using immunohistochemistry, whereas, a positive value was
obtained for each isoenzyme in all the tumour biopsies
subjected to Western blot analysis.
In the patient group studied, clinicopathological features
including FIGO stage, grade of tumour differentiation, post-
operative residual disease status and response to chemother-
apy were found to be highly significant markers of disease
outcome, as would be expected in ovarian cancer. The
glutathione transferase isoenzyme levels (irrespective of the
method of detection and whether the tumour sample was
taken pre- or post-chemotherapy) and the GST activity were,
however, not significantly correlated with response to
treatment, progression-free or overall survival. This is in
agreement with two previous studies in ovarian cancer using
immunohistochemistry only for detection (Murphy et al.,
1992; Van Der Zee et al., 1995) and also with another study
by Van Der Zee (1992), in which GST isoenzyme levels in
ovarian tumours were quantified by HPLC. However, results
contrasting with our study have been found in two further
immunohistochemical studies. In the first (Green et al., 1993)
the intensity of GST acidic isoenzyme staining was
significantly correlated with survival in 78 patients with
ovarian carcinoma, the prognosis being poorer in patients
with a higher intensity of staining in tumour biopsies. In the
second study (Hamada et al., 1994), expression of GST acidic
isoenzyme was again examined immunohistochemically in
relation to response to chemotherapy in 61 patients with
ovarian cancer. This group found that the survival ofpatients
with positive GST acidic isoenzyme tumours was significantly
shorter than those with negative tumours. The value of GST
isoenzymes as markers of disease outcome have been
investigated in other malignancies. In node-negative breast
cancer increased GST acidic isoenzyme measured immuno-
histochemically was associated with decreased disease-free
survival and overall survival (Gilbert et al., 1993), but there
was no correlation between the level of GST isoenzyme
expression and the length of disease-free survival in node-
positive breast cancer when the isoenzymes were quantified
by Western blot (Peters et al., 1993). In gastric cancer an
immunohistochemical study showed no significant correlation
between GST acidic isoenzyme expression and clinicopatho-
logical features or prognosis (Okuyama et al., 1994), but in
oral cancer the acidic isoenzyme was considered to be a
useful aid to early diagnosis, prediction of disease extent and
outcome (Hirata et al., 1992). Immunohistochemical mea-
surements of neutral isoenzymes have shown a positive
correlation with survival in childhood acute lymphoblastic
leukaemia (Hall et al., 1994), and of acidic isoenzymes with
survival in non-lymphoblastic leukaemia in adults (Koberda
and Hellman, 1994).
A further finding from this study was that there was no
significant relationship between the levels of GST isoenzymes
detected in ovarian tumour biopsy samples obtained at initial
surgery (before chemotherapy) and those obtained at second-
look procedures (after chemotherapy). Similarly, no relation-
ship existed between the GST activity measured in ovarian
tumour samples before and after chemotherapy. Earlier in
vitro studies in cell lines exhibiting resistance to platinum
and/or alkylating agents have shown an increased enzymatic
activity of GST (Lewis et al., 1988; Meijer et al., 1990)
suggesting that repeated exposure to such drugs might result
in overexpression of GST. However a study of biopsy
material showed GST acidic levels to be lower in patients
receiving cyclophosphamide and platinum in comparison
with untreated patients (Van Der Zee et al., 1992). In the
current study a relationship was observed between immuno-
histochemically detected acidic GST isoenzyme and the
treatment group comprising combination chemotherapy
(carboplatin, cyclophosphamide, ifosfamide and doxorubi-
cin). Approximately equal numbers of patients in this groupGST acdft and i n. i in ovarian cancer
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had the biopsy sample taken before chemotherapy (n=31)
and after chemotherapy (n=26). The level of GST acidic
isoenzymes in prechemotherapy samples was not used as a
means of selecting the treatment regimen for these patients.
This measurement is, therefore, largely irrelevant-particu-
larly when considering that the GST levels in the
prechemotherapy group of patients bore no relationship to
patient outcome or survival, or to any of the well-recognised
clinicopathological features of ovarian cancer. When
considered alone, the post-chemotherapy samples (n=26)
did not correlate significantly with the type of chemotherapy
the patient had been treated with. Our data did not,
therefore, substantiate earlier findings of any relationship
between the GST isoenzyme level and treatment received.
The results of this study have shown that GST isoenzyme
levels and/or GST activity cannot be used as reliable markers
of disease outcome or survival in patients with ovarian
cancer. However, the Western blot technique of determining
GST isoenzyme levels has been demonstrated to be more
sensitive than immunohistochemistry. It would, therefore,
seem appropriate to suggest that studies in ovarian cancer
where GST isoenzymes have shown positive correlations with
survival using immunohistochemistry should be repeated
employing a semiquantitative method of determining iso-
enzyme levels.
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